For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

The stock market experienced quite a bit of volatility ... Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales ...

To watch more expert insights and analysis on the latest market action ... Despite these headline-grabbing results, Eli Lilly's stock movement remained flat over the last month, aligning with ...

Companies showing rapid sales growth and improving profit margins include Eli Lilly, Micron, AMD and Newmont Every quarter during earnings season it can be useful to see which companies have improved ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

To watch more expert insights and analysis on the latest market action ... GE Vernova and TKO Group Holdings. Eli Lilly stock is hugging its 10-week moving average in a long base, while GE Vernova and ...

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.